Pharmacogenomic Study to Predict Neurotoxicity of Oxaliplatin
In order to explore genetic factors that may determine the neurotoxicity of oxaliplatin-based chemotherapy, germinal gene polymorphisms will be analyzed.
Curatively Resected Stage III Colon Cancer
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Pharmacogenomic Study to Predict Toxicity and Response in Colorectal Cancer Patients Treated With Oxaliplatin-based Chemotherapy|
- neuropathy [ Time Frame: six months ] [ Designated as safety issue: Yes ]
Biospecimen Retention: Samples With DNA
DNA will be extracted from peripheral blood samples using DNA isolation kit.
|Study Start Date:||September 2008|
|Study Completion Date:||April 2010|
|Primary Completion Date:||January 2010 (Final data collection date for primary outcome measure)|
Stage III colorectal cancer patients who are treated with adjuvant FOLFOX chemotherapy
To investigate the impact of single nucleotide (SNP) polymorphism on the toxicity profile in colorectal cancer patients treated with FOLFOX chemotherapy, 10 cc of blood will be drawn in EDTA tube for extraction. DNA will be extracted from peripheral blood samples using DNA isolation kit, and SNP polymorphisms will be evaluated.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00977717
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of, 135 710|
|Principal Investigator:||Se Hoon Park, MD||Samsung Medical Center, Seoul, Korea|